Wall Street analysts expect Masimo Co. (NASDAQ:MASI) to report sales of $201.63 million for the current quarter, Zacks reports. Four analysts have made estimates for Masimo’s earnings. The lowest sales estimate is $201.33 million and the highest is $202.20 million. Masimo posted sales of $183.20 million in the same quarter last year, which would indicate a positive year over year growth rate of 10.1%. The firm is expected to issue its next quarterly earnings results after the market closes on Tuesday, February 27th.
According to Zacks, analysts expect that Masimo will report full-year sales of $201.63 million for the current fiscal year, with estimates ranging from $774.25 million to $775.10 million. For the next year, analysts expect that the business will report sales of $828.57 million per share, with estimates ranging from $810.90 million to $840.03 million. Zacks’ sales averages are an average based on a survey of sell-side research analysts that cover Masimo.
A number of equities analysts have recently weighed in on the stock. Zacks Investment Research raised shares of Masimo from a “hold” rating to a “buy” rating and set a $98.00 price objective for the company in a research report on Thursday, November 2nd. Stifel Nicolaus reaffirmed a “buy” rating and set a $108.00 price target on shares of Masimo in a research report on Friday, November 3rd. Finally, BidaskClub lowered shares of Masimo from a “hold” rating to a “sell” rating in a research report on Thursday, December 7th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $97.17.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Sterling Capital Management LLC grew its stake in Masimo by 0.6% during the second quarter. Sterling Capital Management LLC now owns 7,803 shares of the medical equipment provider’s stock worth $711,000 after buying an additional 44 shares during the period. 1st Global Advisors Inc. grew its stake in Masimo by 3.2% during the second quarter. 1st Global Advisors Inc. now owns 7,468 shares of the medical equipment provider’s stock worth $681,000 after buying an additional 233 shares during the period. Advisor Group Inc. grew its stake in Masimo by 38.4% during the second quarter. Advisor Group Inc. now owns 2,361 shares of the medical equipment provider’s stock worth $216,000 after buying an additional 655 shares during the period. Cardinal Capital Management grew its stake in Masimo by 2.7% during the third quarter. Cardinal Capital Management now owns 25,681 shares of the medical equipment provider’s stock worth $2,222,000 after buying an additional 678 shares during the period. Finally, Strs Ohio grew its stake in Masimo by 3.7% during the third quarter. Strs Ohio now owns 19,700 shares of the medical equipment provider’s stock worth $1,705,000 after buying an additional 700 shares during the period. Institutional investors own 82.57% of the company’s stock.
Masimo (NASDAQ:MASI) opened at $83.47 on Friday. The firm has a market cap of $4,390.00, a P/E ratio of 13.23, a PEG ratio of 3.12 and a beta of 0.85. Masimo has a 52-week low of $75.06 and a 52-week high of $104.71.
TRADEMARK VIOLATION NOTICE: This article was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/02/11/brokerages-anticipate-masimo-co-masi-will-post-quarterly-sales-of-201-63-million.html.
Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.